Iryna Drozd
Shares of Quoin Pharmaceuticals (NASDAQ:QNRX) soared 60% in morning trading Monday on news that the FDA has cleared the company to include teenagers in two clinicals trials for its drug QRX003 in the treatment of Netherton syndrome, a form of skin disorder ichthyosis.
The biotech company said the agency has cleared it to recruit teenagers aged 14 and up to participate in the ongoing trials, which should significantly expand the number of eligible subjects and could lead to a more robust data set.
QRX003 is in Phase 3 testing for Netherton syndrome, according to Quoin’s website.